Get the Stockscreener App
244.96
0.36%
-0.89
Jazz Pharmaceuticals Plc stock is traded at $244.96, with a volume of 542.03K.
It is down -0.36% in the last 24 hours and up +2.90% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$245.85
Open:
$243.59
24h Volume:
542.03K
Relative Volume:
0.63
Market Cap:
$15.90B
Revenue:
$4.44B
Net Income/Loss:
$29.49M
P/E Ratio:
-13,313.04
EPS:
-0.0184
Net Cash Flow:
$1.19B
1W Performance:
-4.52%
1M Performance:
+2.90%
6M Performance:
+47.29%
1Y Performance:
+109.96%
1-Day Range:
$240.63
$245.35
1-Week Range:
$240.63
$261.27
52-Week Range:
$116.53
$265.05
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
244.96 | 16.16B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Understanding HER2 Expression in Gastroesophageal AdenocarcinomaJazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion - AKM.RU
Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed - simplywall.st
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout (JAZZ) - Seeking Alpha
Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
JAZZ Maintained by Morgan Stanley -- Price Target Raised to $283 - GuruFocus
Jazz Pharmaceuticals (JAZZ) Acquires Actio Biosciences for $820 Million - GuruFocus
Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says - marketscreener.com
Morgan Stanley Adjusts Jazz Pharmaceuticals PT to $283 From $280, Maintains Overweight Rating - marketscreener.com
Jazz Pharmaceuticals buys Actio for up to $1.3bn - BioXconomy
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront - Pharmaceutical Technology
Jazz Pharmaceuticals (JAZZ) Short Interest & Short Float | Updated Aug 2026 $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript - The Globe and Mail
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Singapore
Jazz Pharmaceuticals to Acquire Actio Biosciences in Merger - TipRanks
Jazz Pharmaceuticals (JAZZ) plans $820M Actio Biosciences deal plus $500M milestones - Stock Titan
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M By Investing.com - Investing.com India
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Solid Earnings Are Supported By Other Strong Factors - 富途牛牛
Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push - Law360
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal - biopharmadive.com
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio - Reuters
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline - BioSpace
JAZZ Looks 70.7% Overvalued on GF Value™ Amid $820M Actio Biosci - GuruFocus
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Jazz Pharmaceuticals to Acquire Actio Biosciences in Deal Worth Up to $1.32 Billion - citybiz
JAZZ Looks 68.7% Overvalued on GF Value™ After Actio Biosciences Acquisition - GuruFocus
Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio - TipRanks
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M - Investing.com
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, gaining a new epilepsy drug ABS-1230. - Pluang
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio - PR Newswire
Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jazz Pharmaceuticals plc 2026 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) 2026-08-07 - Seeking Alpha
Jazz Pharmaceuticals plc SEC Filing (Aug 7, 2026) - Stock Titan
Jazz Pharmaceuticals plc (JAZZ) News, Articles, Events & Latest Updates - Stocktwits
JAZZ vs. TECH: Which Stock Is the Better Value Option? - Yahoo Finance
FMR LLC and Abigail Johnson disclose 7.4% Jazz Pharmaceuticals (JAZZ) ownership - Stock Titan
Jazz Pharmaceuticals (JAZZ) Director Bruce Cozadd Sells 6,000 Sh - GuruFocus
Jazz Pharmaceuticals Plc Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next - Moomoo
What Does Jazz Pharmaceuticals (JAZZ) Raised Guidance Mean With FDA Decisions Ahead? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Stock May Stay Below Fair Value Following Raised Guidance - simplywall.st
Jazz Pharmaceuticals' Re-Rating Story Has Legs (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals PLC $JAZZ Stake Boosted by Bank of America Corp DE - marketbeat.com
Amundi Acquires 53,454 Shares of Jazz Pharmaceuticals PLC $JAZZ - marketbeat.com
Jazz Pharmaceuticals stock hits all-time high at 261.46 USD - Investing.com
JAZZ PHARMACEUTICALS PLC : PIPER SANDLER RAISES TARGET PRICE TO $310 FROM $301 - webull.com
Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push - simplywall.st
Jazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Jazz Pharmaceuticals stock hits all-time high at 261.46 USD By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):